147 related articles for article (PubMed ID: 27994498)
1. Association between survivin genetic polymorphisms and epidermal growth factor receptor mutation in non-small-cell lung cancer.
Liu TC; Hsieh MJ; Wu WJ; Chou YE; Chiang WL; Yang SF; Su SC; Tsao TC
Int J Med Sci; 2016; 13(12):929-935. PubMed ID: 27994498
[TBL] [Abstract][Full Text] [Related]
2. The Clinical Significance of the Insulin-Like Growth Factor-1 Receptor Polymorphism in Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation.
Liu TC; Hsieh MJ; Liu MC; Chiang WL; Tsao TC; Yang SF
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213344
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.
Winther-Larsen A; Nissen PH; Jakobsen KR; Demuth C; Sorensen BS; Meldgaard P
Lung Cancer; 2015 Nov; 90(2):314-20. PubMed ID: 26386832
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.
Nomura M; Shigematsu H; Li L; Suzuki M; Takahashi T; Estess P; Siegelman M; Feng Z; Kato H; Marchetti A; Shay JW; Spitz MR; Wistuba II; Minna JD; Gazdar AF
PLoS Med; 2007 Apr; 4(4):e125. PubMed ID: 17455987
[TBL] [Abstract][Full Text] [Related]
5. NAT2 fast acetylator genotypes are associated with an increased risk for lung cancer with wildtype epidermal growth factor receptors in Taiwan.
Lee CN; Yu MC; Bai KJ; Chang JH; Fang CL; Hsu HL; Huang BS; Lu PC; Liu HE
Lung Cancer; 2009 Apr; 64(1):9-12. PubMed ID: 18706736
[TBL] [Abstract][Full Text] [Related]
6. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
Sasaki H; Endo K; Takada M; Kawahara M; Kitahara N; Tanaka H; Okumura M; Matsumura A; Iuchi K; Kawaguchi T; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Lung Cancer; 2006 Oct; 54(1):103-8. PubMed ID: 16890322
[TBL] [Abstract][Full Text] [Related]
7. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
[TBL] [Abstract][Full Text] [Related]
8. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.
Okamoto K; Okamoto I; Okamoto W; Tanaka K; Takezawa K; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
Cancer Res; 2010 Dec; 70(24):10402-10. PubMed ID: 21159653
[TBL] [Abstract][Full Text] [Related]
9. Survivin expression impacts prognostically on NSCLC but not SCLC.
Rosato A; Menin C; Boldrin D; Dalla Santa S; Bonaldi L; Scaini MC; Del Bianco P; Zardo D; Fassan M; Cappellesso R; Fassina A
Lung Cancer; 2013 Feb; 79(2):180-6. PubMed ID: 23218791
[TBL] [Abstract][Full Text] [Related]
10. EGFR L858R mutation and polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patients.
Yang SY; Yang TY; Chen KC; Li YJ; Hsu KH; Tsai CR; Chen CY; Hsu CP; Hsia JY; Chuang CY; Tsai YH; Chen KY; Huang MS; Su WC; Chen YM; Hsiung CA; Shen CY; Chang GC; Yang PC; Chen CJ
Clin Cancer Res; 2011 Apr; 17(8):2149-58. PubMed ID: 21300759
[TBL] [Abstract][Full Text] [Related]
11. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
He C; Liu M; Zhou C; Zhang J; Ouyang M; Zhong N; Xu J
Int J Cancer; 2009 Nov; 125(10):2393-9. PubMed ID: 19530244
[TBL] [Abstract][Full Text] [Related]
12. EGFR and erbB2 mutation status in Japanese lung cancer patients.
Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor mutations in 510 Finnish non--small-cell lung cancer patients.
Mäki-Nevala S; Rönty M; Morel M; Gomez M; Dawson Z; Sarhadi VK; Telaranta-Keerie A; Knuuttila A; Knuutila S
J Thorac Oncol; 2014 Jun; 9(6):886-91. PubMed ID: 24828666
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival.
Dai J; Jin G; Dong J; Chen Y; Xu L; Hu Z; Shen H
J Thorac Oncol; 2010 Nov; 5(11):1748-54. PubMed ID: 20881643
[TBL] [Abstract][Full Text] [Related]
15. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
[TBL] [Abstract][Full Text] [Related]
16. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
17. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
[TBL] [Abstract][Full Text] [Related]
18. Correlation of E-cadherin gene polymorphisms and epidermal growth factor receptor mutation in lung adenocarcinoma.
Huang CY; Hsieh MJ; Liu TC; Chiang WL; Liu MC; Yang SF; Tsao TC
Int J Med Sci; 2018; 15(8):765-770. PubMed ID: 30008585
[TBL] [Abstract][Full Text] [Related]
19. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
20. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
Malapelle U; Bellevicine C; De Luca C; Salatiello M; De Stefano A; Rocco D; de Rosa N; Vitiello F; Russo S; Pepe F; Iaccarino A; Micheli P; Illiano A; Carlomagno C; Piantedosi FV; Troncone G
Cancer Cytopathol; 2013 Oct; 121(10):552-60. PubMed ID: 23780873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
